How Long Do You Stay on the Maintenance Dose of Mounjaro?

Step 1: reaching a maintenance dose in the first place

Mounjaro treatment starts at 2.5mg. That first pen exists to let your system adjust, not to drive significant weight loss, most people notice very little change at that level, which is entirely expected. From there, your prescriber typically steps the dose up every four weeks: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and then 15mg. The climb is not compulsory. If you are managing well at 7.5mg and losing weight steadily, your prescriber may keep you there rather than push higher. The maintenance dose is simply the point where titration stops and sustained treatment begins, it is wherever you land when dose increases are no longer needed or tolerable.

People sometimes ask whether lower doses can serve as a long-term maintenance level. The short answer is yes, with the right clinical picture. Our page on whether 5mg qualifies as a maintenance dose covers this in detail, and the NHS medicines information for tirzepatide sets out the licensed dose range clearly.

Step 2: how long maintenance actually lasts

This is where most people expect a neat number and are surprised there isn't one. The UK licence for Mounjaro in weight management does not cap treatment duration. Unlike semaglutide under NICE's TA875, which is explicitly approved for a maximum of two years in NHS specialist settings, NICE's appraisal of tirzepatide (TA1026, published December 2024) does not set an equivalent time limit for private use. The clinical trigger for reviewing continuation is performance, not the calendar: if you have not achieved at least 5% weight loss after six months at the highest dose you tolerate, the guidance suggests discussing whether to carry on. If you are losing weight well and tolerating the medicine, there is no clinical rule that ends treatment at month twelve or twenty-four.

In practice, many people stay on their maintenance dose for years. Weight is a chronic condition with biological drivers; the appetite and metabolic effects of tirzepatide are active only while you are taking it. That is worth knowing. Our page on what weight loss looks like at maintenance goes into the evidence in more depth, including what the SURMOUNT-1 trial showed about the weight-regain curve after stopping.

Step 3: what a responsible review at each repeat looks like

At nume, no prescription renews automatically. A GPhC-registered Independent Prescriber reads your answers (weight, any new symptoms, how you are tolerating the dose) before every repeat is approved. That is not bureaucracy for its own sake; it is the structure that makes long-term treatment safe. Weight regain after stopping is well-documented in clinical trial data, so that conversation is part of every review: are you still benefiting, and if you were to stop, what would the plan be?

If you are on a clinical review and wondering whether your dose is right, the overview of Mounjaro 5mg or the fuller picture on what treatment costs over time may help you frame the right questions. The weight-loss treatment overview on our site is also a useful reference for putting Mounjaro in context alongside other options.

Stopping, stepping down, or continuing: how the decision is made

There is no universally right answer. Some people reach a weight they are happy with and want to try stepping down; others treat maintenance as indefinite. The NICE committee discussion around TA1026 acknowledged that weight regain after stopping is a real clinical concern, and that longer-term treatment may be appropriate for many patients. What the prescriber is looking for at each review is a simple question: is continued treatment still clinically justified and well-tolerated?

Side effects usually settle during titration, but new symptoms at maintenance (persistent nausea, changes in digestion, any abdominal pain) should always be reported rather than waited out. The NHS tirzepatide medicines page lists side effects and what to do; anything severe, particularly stomach pain that spreads to the back, warrants same-day medical attention. Reporting unexpected effects through the MHRA's Yellow Card scheme also helps build the long-term safety picture for everyone using this medicine.

If you have questions about your specific situation, or you are considering starting treatment, our prescribers are the right people to talk it through with. Speak to our prescribers by starting a free consultation at our treatment page, there is no obligation, and the clinical review happens the same day.